# Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)

> **NCT00928200** · PHASE1 · TERMINATED · sponsor: **Therapeutic Advances in Childhood Leukemia Consortium** · enrollment: 1 (actual)

## Conditions studied

- Relapsed Acute Lymphoblastic Leukemia
- Allergy to PEG e.Coli Asparaginase
- Allergy to Native e.Coli Asparaginase

## Interventions

- **DRUG:** Erwinase
- **DRUG:** Vincristine
- **DRUG:** Dexamethasone
- **DRUG:** Doxorubicin
- **DRUG:** Cytarabine
- **DRUG:** Methotrexate
- **DRUG:** Triple Intrathecal Therapy
- **DRUG:** Dexrazoxane

## Key facts

- **NCT ID:** NCT00928200
- **Lead sponsor:** Therapeutic Advances in Childhood Leukemia Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-04-13
- **Primary completion:** 2010-06-04
- **Final completion:** 2010-06-04
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Study was terminated due to lack of accrual.
- **Last updated:** 2019-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00928200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00928200, "Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00928200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*